June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Integration of Mobile Health and Biobank to Establish the Dry Eye Data Platform
Author Affiliations & Notes
  • Yasutsugu Akasaki
    Ophthalmology, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo-ku, Tokyo, Japan
    Digital medicine, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo-ku, Tokyo, Japan
  • Nobuo Fuse
    Tohoku Medical Megabank Organization, Tohoku Daigaku, Sendai, Miyagi, Japan
  • Soichi Ogishima
    Tohoku Medical Megabank Organization, Tohoku Daigaku, Sendai, Miyagi, Japan
  • Akira Uruno
    Tohoku Medical Megabank Organization, Tohoku Daigaku, Sendai, Miyagi, Japan
  • Atsushi Shimizu
    Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Japan
  • Tomohiro Nakamura
    Tohoku Medical Megabank Organization, Tohoku Daigaku, Sendai, Miyagi, Japan
  • Fuji Nagami
    Tohoku Medical Megabank Organization, Tohoku Daigaku, Sendai, Miyagi, Japan
  • Makiko Taira
    Tohoku Medical Megabank Organization, Tohoku Daigaku, Sendai, Miyagi, Japan
  • Masahiro Nakamura
    Digital medicine, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo-ku, Tokyo, Japan
    Bioengineering,Graduate School of Engineering, Precision Health, Tokyo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Jun Seita
    Advanced Data Science Project, RIKEN Information R&D and Strategy Headquarters, Japan
  • Jaemyoung Sung
    Ophthalmology, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo-ku, Tokyo, Japan
    University of South Florida Morsani College of Medicine, Tampa, Florida, United States
  • Atsuko Eguchi
    Hospital Administration, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo-ku, Tokyo, Japan
  • Akie Midorikawa-Inomata
    Hospital Administration, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo-ku, Tokyo, Japan
  • Akira Murakami
    Ophthalmology, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo-ku, Tokyo, Japan
    Digital medicine, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo-ku, Tokyo, Japan
  • Takenori Inomata
    Ophthalmology, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo-ku, Tokyo, Japan
    Digital medicine, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo-ku, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Yasutsugu Akasaki johnson & johnson, Code F (Financial Support); Nobuo Fuse None; Soichi Ogishima None; Akira Uruno None; Atsushi Shimizu None; Tomohiro Nakamura None; Fuji Nagami None; Makiko Taira None; Masahiro Nakamura johnson & johnson, Code F (Financial Support); Jun Seita None; Jaemyoung Sung None; Atsuko Eguchi None; Akie Midorikawa-Inomata InnoJin, Inc., Code E (Employment); Akira Murakami Johnson & Johnson Vision Care,Santen Pharmaceutical Co., Ltd.,SEED Co., Ltd.,Kowa Company, Ltd., Code F (Financial Support), Johnson & Johnson Vision Care,Santen Pharmaceutical Co.,Kowa Company, Ltd., Code R (Recipient); Takenori Inomata Santen Pharmaceutical Co., Ltd., Code C (Consultant/Contractor), InnoJin, Inc., Code E (Employment), Novartis Pharma KK, Santen Pharmaceutical Co., Ltd.,SEED Co., Ltd.,Johnson & Johnson, , Code F (Financial Support), InnoJin, Inc., Code P (Patent)
  • Footnotes
    Support  This research was supported by JST COI [Grant Number: JPMJCER02WD02] (T.I.)] and JSPS KAKENHI [Grant Numbers: 20KK0207 (T.I.), 20K23168 (A.M.I.), 21K17311 (A.M.I.), 21K20998 (A.E.)], and 22K16983 (A.E.)]. The Kondou Kinen Medical Foundation, Medical Research Encouragement Prize 2020 (T.I.), Charitable Trust Fund for Ophthalmic Research in Commemoration of Santen Pharmaceutical’s Founder 2020 (T.I.), Nishikawa Medical Foundation, Medical Research Encouragement Prize 2020 (T.I.), Terumo Life Science Foundation (T.I.), OTC Self-Medication Promotion Foundation 2020 (Y.O.) and 2021 (T.I.), Medical Research Encouragement Prize 2022, Cell Science Research Foundation (T.I.), and Takeda Science Foundation (T.I.) also helped fund this study. The sponsors had no role in the design or performance of the study, in data collection and management, in the analysis and interpretation of the data, in the preparation, review, or approval of the manuscript, or in the decision to submit the manuscript for publication.
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3953. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yasutsugu Akasaki, Nobuo Fuse, Soichi Ogishima, Akira Uruno, Atsushi Shimizu, Tomohiro Nakamura, Fuji Nagami, Makiko Taira, Masahiro Nakamura, Jun Seita, Jaemyoung Sung, Atsuko Eguchi, Akie Midorikawa-Inomata, Akira Murakami, Takenori Inomata; Integration of Mobile Health and Biobank to Establish the Dry Eye Data Platform. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3953.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To establish a comprehensive database for dry eye by incorporating a mobile health (mHealth) app to the Tohoku Medical Megabank Organization (ToMMo) cohort study.

Methods : Among ToMMo cohort study participants above the age of 20 who have received a health examination at the Sendai community support center, additional examination was performed using DryEyeRhythm, an mHealth app for dry eye research. Electronic consent was obtained through the app. Dry eye-related information was collected, including disease-specific questionnaire (Japanese version of Ocular Surface Disease Index, J-OSDI) responses, maximum blink interval (MBI), demographics, and lifestyle patterns. A second examination was performed 1 month after the initial exam using the same app. Users with reported J-OSDI > 13 total points and measured MBI < 12.4 seconds were determined as having “app-based dry eye.”

Results : 2,701 individuals visited the Sendai community support center for an examination between August 2021 and June 2022. Of these people 1,380 individuals agreed to participate. 1,220 participants (mean age 51.4±14.0; female 74.4%) were included and a total of 4,536 DryEyeRhythm data points were collected. 379 participants met the criteria for app-based dry eye (31.1%; mean age 52.7±14.0; female 85.0%). J-OSDI and MBI were significantly worse in participants with app-based dry eye compared to those without app-based dry eye (median [IQR], J-OSDI: 22.9 [18.2-33.3] vs 8.3 [4.2-12.5], P < 0.001; MBI: 2.3 [0.9-6.9] vs 15.7 [3.5-30], P < 0.001). 634 (52.0%) participants received a second examination using DryEyeRhythm.

Conclusions : This is the first known study to create a comprehensive database for dry eye that integrates genomics and personalized health data with traditional dry eye-related markers in the population-based cohort study. These results may have implications for future clinical implementations of biobank data, bringing genomic medicine to practice.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×